Home › Funds › Burkehill Global Management, LP › DYN
Burkehill Global Management, LP position in DYN
DYNE THERAPEUTICS INC · Health Care
Burkehill Global Management, LP reported holding 400,000 shares of DYN (DYNE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.4M, representing 0.28% of its reported portfolio and ranking #45 among its reported holdings. Burkehill Global Management, LP has disclosed DYN holdings in 4 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Burkehill Global Management, LP's DYN position evolved
Burkehill Global Management, LP first disclosed a stake in DYN in Q3 2025 at 120,000 shares (US$1.5M). The position peaked in Q3 2026 at 400,000 shares, worth US$6.4M. Across 4 filings, Burkehill Global Management, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 400,000 shares valued at US$6.4M. Notable position changes include a 29% increase in Q4 2025 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 120.00K | $1.52M | New |
| Q4 2025 | 155.00K | $3.03M | Add |
| Q1 2026 | 155.00K | $2.81M | Hold |
| Q3 2026 | 400.00K | $6.44M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DYN and 13F data
DYN (DYNE THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in DYN — the largest reported positions include Vestal Point Capital, LP (US$99.9M), TCG Crossover Management, LLC (US$74.3M), Frazier Life Sciences Management, L.P. (US$62.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Vestal Point Capital, LP 6.20M sh · $99.88M · Q3 2026
- TCG Crossover Management, LLC 4.62M sh · $74.35M · Q3 2026
- Frazier Life Sciences Management, L.P. 3.85M sh · $62.07M · Q3 2026
- FCPM III SERVICES B.V. 3.59M sh · $57.78M · Q3 2026
- Atlas Venture Life Science Advisors, LLC 3.44M sh · $55.43M · Q3 2026
- MPM BioImpact LLC 3.21M sh · $51.68M · Q3 2026
- Logos Global Management LP 3.00M sh · $48.33M · Q3 2026
- ARMISTICE CAPITAL, LLC 2.68M sh · $43.14M · Q3 2026
- Sofinnova Investments, Inc. 2.51M sh · $40.45M · Q3 2026
- Siren, L.L.C. 2.43M sh · $39.13M · Q3 2026
- Venrock Adviser, LLC 2.17M sh · $35.02M · Q3 2026
- Bain Capital Life Sciences Investors, LLC 1.90M sh · $30.61M · Q3 2026
More on Burkehill Global Management, LP
FAQ
How long has Burkehill Global Management, LP held DYN?
Burkehill Global Management, LP has disclosed DYN holdings in 4 of the last 5 reported quarters, going back to Q3 2025.
What is Burkehill Global Management, LP's current position in DYN?
As of Q3 2026, Burkehill Global Management, LP holds 400.00K shares of DYN (DYNE THERAPEUTICS INC), valued at $6.44M, representing 0.28% of its reported portfolio and ranking #45.
Has Burkehill Global Management, LP been buying or selling DYN?
In the latest 13F filing (Q3 2026), Burkehill Global Management, LP newly opened its position in DYN. The position peaked in Q3 2026 at 400.00K shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Vestal Point Capital, LP, TCG Crossover Management, LLC, Frazier Life Sciences Management, L.P., among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.